Generics proposal pulled
This article was originally published in The Tan Sheet
Executive Summary
FDA withdraws Aug. 6, 1999 proposed rule on 180-day generic exclusivity and ANDA approvals "in light of [court] decisions" invalidating agency's position on which rulings in patent infringement suits can trigger 180-day period. Proposal stated FDA would not start the clock until after a court decision from which no appeal could be taken, but a January 2000 D.C. federal court concluded 180 days was triggered by trial court decision on patent invalidity. Agency's most recent Hatch/Waxman proposed rule does not discuss the 180-day provision (1"The Tan Sheet" Oct. 28, 2002, p. 10). FDA will "carefully evaluate possible options for future rulemaking addressing 180-day exclusivity and the timing of ANDA approvals," agency says in 2Nov. 1 Federal Register notice...
You may also be interested in...
Hatch/Waxman Reinterpretation Underpins Change In 30-Month Stay Policy
FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Hatch/Waxman language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.